title: [A clinical study on multi-disciplinary team and surgery for resectable colorectal cancer with liver metastases].
abstract: OBJECTIVE
  To analyze the survival outcomes of the surgery for colorectal cancer with liver metastases (CRCLM), and study the mode of multi-disciplinary team (MDT) for CRCLM.
  
  
  METHODS
  The retrospective analysis was conducted for 38 patients with CRCLM received MDT management and surgical treatment from January 2009 to August 2011. The peri-operative and survival outcomes of MDT and surgery were evaluated.
  
  
  RESULTS
  All the cases met the present criteria of resetability for CRCLM, but only 4 cases (10.5%) met the previous one. Coloproctectomy and hepatectomy were performed in all cases, with 39 colorectal neoplasms and 155 liver lesions removed. One case died of postoperative septic shock. Colorectal and hepatic specific complications were absent in the others patients except one case of biliary leak which was treated with conservative management. Neoadjuvant chemotherapy was arranged in 13 cases. Adjuvant chemotherapy was administered for every patient. After a mean follow-up of (22 ± 10) months according to the finding time of liver metastases, recurrence and metastases were observed in 16 cases and 6 cases died of late-stage cachexia. The 1-, 2- and 3-overall survival rate were 94.4%, 85.3% and 75.8% respectively, and the 1-, 2- and 3-disease-free survival rate were 70.1%, 54.2% and 54.2% respectively.
  
  
  CONCLUSIONS
  MDT mode for resectable CRCLM is recommendable. Surgical resection of CRCLM is feasible and safe, which seems to achieve favourable short-middle oncologic outcomes. And long-term survival is expected.
authors.affiliation: Department of General Surgery, Peking University Third Hospital, Beijing 100191, China.
authors.forename: Hong-Wei
authors.initials: HW
authors.lastname: Yao
authors.forename: Dian-rong
authors.initials: DR
authors.lastname: Xiu
authors.forename: Wei
authors.initials: W
authors.lastname: Fu
authors.forename: Jiong
authors.initials: J
authors.lastname: Yuan
authors.forename: Bin
authors.initials: B
authors.lastname: Jiang
authors.forename: De-chen
authors.initials: DC
authors.lastname: Wang
authors.forename: Chao-lai
authors.initials: CL
authors.lastname: Ma
authors.forename: Chun-hui
authors.initials: CH
authors.lastname: Yuan
authors.forename: Tao
authors.initials: T
authors.lastname: Sun
authors.forename: Li-wen
authors.initials: LW
authors.lastname: Ma
authors.forename: Bao-shan
authors.initials: BS
authors.lastname: Cao
authors.forename: Jian-yu
authors.initials: JY
authors.lastname: Liu
authors.forename: Ming
authors.initials: M
authors.lastname: Chen
authors.forename: Wen
authors.initials: W
authors.lastname: Chen
authors.forename: Shi
authors.initials: S
authors.lastname: Tan
authors.forename: Yong-hui
authors.initials: YH
authors.lastname: Huang
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.forename: Xue-ying
authors.initials: XY
authors.lastname: Shi
mesh_terms: D000328:Adult; D000368:Aged; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome